Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-23 04:55 | 2025-05-20 | ARDX | Ardelyx Inc. | Williams Laura A | Officer | SELL | $4.08 | 6,421 | $26,207 | 402,583 |
| 2025-05-23 04:53 | 2025-05-20 | ARDX | Ardelyx Inc. | Renz Justin A | Officer | SELL | $4.08 | 7,218 | $29,460 | 416,089 |
| 2025-05-23 04:51 | 2025-05-20 | ARDX | Ardelyx Inc. | Kelliher Mike | Officer | SELL | $4.08 | 14,522 | $59,270 | 282,158 |
| 2025-05-23 04:49 | 2025-05-20 | ARDX | Ardelyx Inc. | Foster Eric Duane | Officer | SELL | $4.08 | 2,507 | $10,232 | 316,806 |
| 2025-05-23 00:00 | 2025-05-20 | SPRY | ARS Pharmaceuticals, Inc. | Fitzpatrick Alexander A | Officer | OPT+S | $14.10 | 102,969 | $1,451,513 | 89,613 |
| 2025-05-22 23:05 | 2025-05-22 | SLS | SELLAS Life Sciences Group, Inc. | Kalin Katherine Bach | Director | BUY | $1.80 | 20,000 | $36,000 | 41,000 |
| 2025-05-23 04:52 | 2025-05-20 | ARDX | Ardelyx Inc. | RAAB MICHAEL | Director, Officer | SELL | $4.08 | 46,817 | $191,079 | 1,547,937 |
| 2025-05-22 23:05 | 2025-05-20 | RCKT | ROCKET PHARMACEUTICALS, INC. | Militello John | Officer | SELL | $6.45 | 357 | $2,301 | 64,027 |
| 2025-05-22 23:05 | 2025-05-20 | RCKT | ROCKET PHARMACEUTICALS, INC. | Schwartz Jonathan David | Officer | SELL | $6.45 | 801 | $5,163 | 235,255 |
| 2025-05-22 23:05 | 2025-05-20 | RCKT | ROCKET PHARMACEUTICALS, INC. | Patel Kinnari | Officer | SELL | $6.45 | 767 | $4,944 | 441,927 |
| 2025-05-22 23:05 | 2025-05-20 | RCKT | ROCKET PHARMACEUTICALS, INC. | Shah Gaurav | Director, Officer | SELL | $6.45 | 2,253 | $14,523 | 786,806 |
| 2025-05-22 23:05 | 2025-05-20 | RCKT | ROCKET PHARMACEUTICALS, INC. | Wilson Martin | Officer | SELL | $6.45 | 587 | $3,784 | 149,163 |
| 2025-05-23 00:00 | 2025-05-20 | SPRY | ARS Pharmaceuticals, Inc. | SAUNDERS BRENT L | Director | OPT+S | $14.25 | 120,000 | $1,710,024 | 0 |
| 2025-05-23 04:50 | 2025-05-20 | ARDX | Ardelyx Inc. | GRAMMER ELIZABETH A | Officer | SELL | $4.08 | 5,992 | $24,456 | 311,731 |
| 2025-05-22 23:01 | 2025-05-20 | GYRE | GYRE THERAPEUTICS, INC. | Ma Songjiang | Director, Officer | SELL | $11.04 | 4,000 | $44,160 | 2,810,824 |
| 2025-05-23 00:20 | 2025-05-20 | INSM | INSMED Inc | Desjardins Clarissa | Director | BUY | $66.68 | 3,025 | $201,694 | 3,025 |
| 2025-05-23 00:18 | 2025-05-20 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $67.66 | 27,887 | $1,886,957 | 233,924 |
| 2025-05-22 23:48 | 2025-05-20 | CORT | CORCEPT THERAPEUTICS INC | Robb Gary Charles | Officer | SELL | $75.85 | 2,279 | $172,862 | 16,586 |
| 2025-05-23 01:27 | 2025-05-21 | ATOS | ATOSSA THERAPEUTICS, INC. | QUAY STEVEN C | Director, Officer | BUY | $0.88 | 11,239 | $9,887 | 13,898 |
| 2025-05-22 03:07 | 2025-05-19 | NKTR | NEKTAR THERAPEUTICS | Wilson Mark Andrew | Officer | SELL | $0.67 | 9,996 | $6,697 | 314,296 |
| 2025-05-22 03:08 | 2025-05-19 | NKTR | NEKTAR THERAPEUTICS | Zalevsky Jonathan | Officer | SELL | $0.67 | 10,712 | $7,177 | 305,892 |
| 2025-05-21 23:37 | 2025-05-19 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $26.41 | 12,000 | $316,920 | 72,363 |
| 2025-05-22 01:31 | 2025-05-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $16.31 | 5,000 | $81,534 | 985,188 |
| 2025-05-22 01:29 | 2025-05-19 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $16.49 | 5,000 | $82,453 | 972,892 |
| 2025-05-21 19:57 | 2025-05-20 | MDCX | Medicus Pharma Ltd. | VELOCITY FUND PARTNERS, LP | 10% owner | SELL | $7.72 | 75,000 | $578,940 | 3,248,741 |
| 2025-05-22 02:11 | 2025-05-20 | XOMA | XOMA Royalty Corp | BURNS THOMAS M. | Officer | OPT+S | $25.38 | 10,482 | $266,033 | 22,563 |
| 2025-05-22 02:11 | 2025-05-20 | XOMA | XOMA Royalty Corp | Hughes Owen | Director, Officer | OPT+S | $25.38 | 25,637 | $650,667 | 62,701 |
| 2025-05-21 23:13 | 2025-05-20 | PHIO | Phio Pharmaceuticals Corp. | Ferrara Robert L | Director | BUY | $1.82 | 2,500 | $4,550 | 13,166 |
| 2025-05-21 23:50 | 2025-05-19 | AEON | Aeon Biopharma Inc. | FISCHER JOST | Director | BUY | $0.50 | 110,000 | $55,297 | 206,785 |
| 2025-05-22 04:23 | 2025-05-21 | VNDA | Vanda Pharmaceuticals Inc. | Polymeropoulos Mihael Hristos | Director, Officer | BUY | $4.40 | 10,000 | $43,995 | 2,325,731 |
| 2025-05-21 23:01 | 2025-05-21 | ZOMDF | Zomedica Corp. | Blair Anthony K | Officer | BUY | $0.05 | 100,000 | $4,960 | 1,000,000 |
| 2025-05-22 03:07 | 2025-05-19 | NKTR | NEKTAR THERAPEUTICS | ROBIN HOWARD W | Director, Officer | SELL | $0.67 | 23,208 | $15,549 | 1,063,693 |
| 2025-05-21 00:44 | 2025-05-20 | CNTA | Centessa Pharmaceuticals plc | SAHA SAURABH | Director, Officer | OPT+S | $12.71 | 55,000 | $699,111 | 221,017 |
| 2025-05-20 23:35 | 2025-05-16 | HCWB | HCW Biologics Inc. | Wong Hing C | Director, Officer, 10% owner | BUY | $7.45 | 8,054 | $60,002 | 501,911 |
| 2025-05-20 23:35 | 2025-05-16 | HCWB | HCW Biologics Inc. | Winer Gary M | Director | BUY | $7.45 | 1,342 | $9,998 | 4,075 |
| 2025-05-20 23:37 | 2025-05-19 | ARQT | Arcutis Biotherapeutics Inc. | Edwards Larry Todd | Officer | SELL | $14.07 | 7,451 | $104,850 | 183,104 |
| 2025-05-21 01:06 | 2025-05-19 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | OPT+S | $33.38 | 101,156 | $3,376,739 | 4,798,447 |
| 2025-05-21 04:45 | 2025-05-20 | MNKD | MANNKIND CORP | Binder Steven B. | Director | SELL | $4.40 | 12,078 | $53,143 | 989,343 |
| 2025-05-20 23:01 | 2025-05-19 | ZOMDF | Zomedica Corp. | DeHaan-Fullerton Karen | Officer | BUY | $0.05 | 104,300 | $5,006 | 104,300 |
| 2025-05-20 23:16 | 2025-05-08 | MTVA | MetaVia Inc. | DONG-A ST CO., LTD | 10% owner | BUY | $0.71 | 4,647,887 | $3,300,000 | 9,995,679 |
| 2025-05-21 04:46 | 2025-05-20 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Director | SELL | $107.49 | 3,000 | $322,473 | 54,137 |
| 2025-05-21 01:03 | 2025-05-16 | RLMD | RELMADA THERAPEUTICS, INC. | Kelly Paul Edward | Director, Officer | BUY | $0.43 | 200,000 | $86,060 | 412,295 |
| 2025-05-21 01:03 | 2025-05-16 | RLMD | RELMADA THERAPEUTICS, INC. | Shenouda Maged | Officer | BUY | $0.49 | 200,000 | $97,200 | 288,335 |
| 2025-05-21 01:02 | 2025-05-16 | RLMD | RELMADA THERAPEUTICS, INC. | Ence Chuck | Officer | BUY | $0.45 | 228,961 | $103,330 | 267,931 |
| 2025-05-21 01:01 | 2025-05-16 | RLMD | RELMADA THERAPEUTICS, INC. | TRAVERSA SERGIO | Director, Officer | BUY | $0.50 | 350,000 | $174,720 | 734,024 |
| 2025-05-21 02:54 | 2025-05-20 | VSTM | Verastem, Inc. | Calkins Daniel | Officer | SELL | $8.13 | 11,143 | $90,593 | 114,055 |
| 2025-05-21 02:52 | 2025-05-20 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $8.13 | 58,677 | $477,044 | 461,982 |
| 2025-05-20 23:14 | 2025-05-16 | IRWD | IRONWOOD PHARMACEUTICALS INC | MCCOURT Thomas A | Director, Officer | SELL | $0.58 | 13,353 | $7,745 | 1,147,281 |
| 2025-05-20 23:10 | 2025-05-16 | IRWD | IRONWOOD PHARMACEUTICALS INC | Gaskins Tammi L | Officer | SELL | $0.58 | 2,563 | $1,487 | 242,596 |
| 2025-05-21 02:28 | 2025-05-19 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $11.84 | 2,600 | $30,791 | 95,557 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.